Whitehawk Therapeutics (NASDAQ:WHWK) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Whitehawk Therapeutics (NASDAQ:WHWK) from a sell rating to a hold rating in a research report sent to investors on Saturday morning.

Other analysts have also issued reports about the stock. Weiss Ratings lowered shares of Whitehawk Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a research note on Friday, June 5th. Oppenheimer restated an “outperform” rating and issued a $7.00 price target on shares of Whitehawk Therapeutics in a research report on Friday, May 8th. B. Riley Financial began coverage on Whitehawk Therapeutics in a report on Thursday, June 25th. They issued a “buy” rating and a $10.00 price target on the stock. Leerink Partners initiated coverage on Whitehawk Therapeutics in a research report on Monday, July 13th. They set an “outperform” rating and a $9.00 price objective for the company. Finally, Citigroup assumed coverage on Whitehawk Therapeutics in a research note on Thursday, April 16th. They set an “outperform” rating for the company. Six analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Whitehawk Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $8.20.

Whitehawk Therapeutics Trading Down 4.4%

Shares of Whitehawk Therapeutics stock opened at $4.55 on Friday. The company’s 50-day moving average price is $4.11 and its two-hundred day moving average price is $3.80. Whitehawk Therapeutics has a 52 week low of $1.57 and a 52 week high of $5.49. The stock has a market cap of $225.00 million, a PE ratio of -4.06 and a beta of 0.76.

Whitehawk Therapeutics (NASDAQ:WHWK) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.20) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.10. On average, equities analysts predict that Whitehawk Therapeutics will post -1.37 EPS for the current fiscal year.

Institutional Trading of Whitehawk Therapeutics

Several large investors have recently added to or reduced their stakes in the company. Quadrature Capital Ltd acquired a new stake in shares of Whitehawk Therapeutics in the fourth quarter worth $28,000. OMERS ADMINISTRATION Corp acquired a new position in Whitehawk Therapeutics during the first quarter valued at $40,000. Dimensional Fund Advisors LP acquired a new position in Whitehawk Therapeutics during the third quarter valued at $84,000. Deutsche Bank AG purchased a new stake in Whitehawk Therapeutics in the 2nd quarter worth about $145,000. Finally, Squarepoint Ops LLC purchased a new stake in Whitehawk Therapeutics in the 3rd quarter worth about $159,000. 52.08% of the stock is owned by institutional investors and hedge funds.

Whitehawk Therapeutics Company Profile

Aadi Bioscience, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.